Drugs / AZD4877
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials · 1 missed | ||||||
| Phase 1 | NCT00613652 | Jan 2008 → Jun 2009 | carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00486265 | Jul 2007 → Jul 2009 | acute myeloid leukemia | AstraZeneca | Terminated | Missed primary |
| Phase 1 | NCT00471367 | Apr 2007 → Dec 2008 | non-Hodgkin lymphoma | AstraZeneca | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT00460460 | Mar → Aug 2007 | lymphoma | AstraZeneca | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT00389389 | Sep 2006 → Aug 2008 | neoplasm | AstraZeneca | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT00661609 | May 2008 → May 2009 | bladder transitional cell carcinoma, renal pelvis carcinoma, ureter cancer, urethra cancer | AstraZeneca | Completed | Missed primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD4877 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00460460 ↗ |
| Action | Inhibit | “AZD4877 is an Eg5 or Kinesin Spindle Protein inhibitor” NCT00471367 ↗1“Kinesin-like protein 1 inhibitor” CHEMBL1829433 ↗ |
| Modality | Small molecule | — CHEMBL1829433 ↗ |
| Route | Intravenous | “intravenous infusion” NCT00389389 ↗ |
| Target | KIF11 | “Kinesin-like protein 1 inhibitor” CHEMBL1829433 ↗ |